FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes

The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.